GlaxoSmithKline plc (LON:GSK) insider Emma Walmsley acquired 8 shares of the stock in a transaction that occurred on Tuesday, December 10th. The shares were bought at an average price of GBX 1,731 ($22.77) per share, with a total value of £138.48 ($182.16).
Emma Walmsley also recently made the following trade(s):
- On Monday, November 11th, Emma Walmsley acquired 7 shares of GlaxoSmithKline stock. The stock was bought at an average cost of GBX 1,727 ($22.72) per share, with a total value of £120.89 ($159.02).
- On Wednesday, October 9th, Emma Walmsley bought 7 shares of GlaxoSmithKline stock. The stock was bought at an average price of GBX 1,729 ($22.74) per share, for a total transaction of £121.03 ($159.21).
Shares of GSK stock traded up GBX 2.80 ($0.04) during trading hours on Wednesday, hitting GBX 1,753 ($23.06). 6,938,436 shares of the company’s stock traded hands, compared to its average volume of 9,120,000. The stock has a market cap of $87.55 billion and a PE ratio of 19.20. The stock’s 50 day simple moving average is GBX 1,725.16 and its 200 day simple moving average is GBX 1,662.96. The company has a quick ratio of 0.50, a current ratio of 0.82 and a debt-to-equity ratio of 183.00. GlaxoSmithKline plc has a 12 month low of GBX 1,421.80 ($18.70) and a 12 month high of GBX 1,796.40 ($23.63).
The firm also recently disclosed a dividend, which will be paid on Thursday, January 9th. Investors of record on Thursday, November 14th will be paid a GBX 19 ($0.25) dividend. The ex-dividend date is Thursday, November 14th. This represents a dividend yield of 1.07%. GlaxoSmithKline’s dividend payout ratio is 1.01%.
A number of analysts have weighed in on GSK shares. Credit Suisse Group boosted their target price on shares of GlaxoSmithKline from GBX 1,700 ($22.36) to GBX 1,800 ($23.68) and gave the stock a “neutral” rating in a research note on Thursday, October 31st. Citigroup reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note on Thursday, November 7th. DZ Bank raised their price objective on GlaxoSmithKline from GBX 1,850 ($24.34) to GBX 2,000 ($26.31) and gave the company a “buy” rating in a report on Thursday, October 31st. Goldman Sachs Group set a GBX 1,900 ($24.99) price objective on GlaxoSmithKline and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Finally, JPMorgan Chase & Co. set a GBX 1,700 ($22.36) target price on GlaxoSmithKline and gave the stock a “neutral” rating in a report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, ten have issued a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of GBX 1,794.64 ($23.61).
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Recommended Story: Put Option Volume
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.